Adjuvant and neoadjuvant therapies of pancreatic cancer: A review

International Journal of Pancreatology

Volumn 29, Issue 1, 2001, Pages 1-7

  Harris, J ^a   Bruckner, H ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adjuvant therapy; Chemotherapy radiotherapy of pancreatic cancer; Neoadjuvant therapy; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MITOMYCIN C;

BEAM THERAPY; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; MULTIMODALITY CANCER THERAPY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS RESECTION; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SURVIVAL RATE;

EID: 0034822034     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1385/ijgc:29:1:01     Document Type: Review

References (45)

1. Treatment of pancreatic cancer
2. Adenocarcinoma of the pancreas: Recent controversies, current management and future therapies
3. The surgical treatment of pancreatic carcinoma
4. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivor
5. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection
6. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer
7. Studies on fluorinated pyrimidines II. Effects on transplanted tumors
8. Effects of combined roentgen irradiation and chemotherapy on transplanted tumors in mice
9. Treatment of malignant neoplasms of the gastrointestinal tract with a combination of 5-fluorouracil and radiation. A randomized double-blind study
10. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil) and high dose radiation + 5-fluorouracil
11. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer
12. Ten-year follow-up of first generation surgical adjuvant, studies of the Gastrointestinal Tumor Study Group. Adjuvant Therapy of Cancer VI
13. Pancrecticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective single-institution experience
14. The Whipple procedure and other standard operative approaches to pancreatic cancer
15. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy
16. Conventional external irradiation alone as adjuvant treatment in resectable pancreatic cancer: Results of a prospective study
17. Adjuvant radiation therapy for pancreatic cancer: A 15-year experience
18. Results of pancreatectomy with radiation therapy for pancreatic cancer
19. Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer
20. Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas
21. Phase I-II study of prophylactic hepatic irradiation with local irradiation and systemic chemotherapy for adenocarcinoma of the pancreas
22. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation ±5-fluorouracil
23. Adjuvant radiochemotherapy following resection of pancreatic adenocarcinoma. Preliminary results
24. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-results of controlled, prospective, randomized multicentre study
25. ESPAC-1 trial progress report: The European randomized adjuvant study comparing radiochemotherapy, 6 months chemotherapy and combination therapy versus observation in pancreatic cancer
26. Adjuvant chemotherapy in pancreatic cancer
27. ESPAC-1 Interim results: A European, randomized study to assess the roles of adjuvant chemotherapy (5FU + folinic acid) and adjuvant chemoradiation (40 GY + 5RU) in resectable pancreatic cancer
28. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region
29. Patterns of failure after curative resection of pancreatic carcinoma
30. Clinical experience with gemcitabine in pancreatic carcinoma
31. Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma
32. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum
33. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A phase II study
34. Preoperative chemoradiation and pancreaticoduodenectomy for adrenocarcinoma of the pancreas
35. Neoadjuvant therapy for unresectable adenocarcinoma of the pancreas
36. The evidence for multimodality treatment of pancreatic cancer
37. A Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized resectable adenocarcinoma of the pancreas: An Eastern Cooperative Oncology Group Study
38. Preoperative irradiation in carcinoma of the pancreas
39. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas
40. Combined modality therapy for stage II and stage III pancreatic cancer
41. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial
42. Continuous infusion (CI) 5-fluorouracil (5-FU), calcium leucovorin (LV) mitomycin C (Mito C) and dipyridamole (D) treatment for patients with locally advanced pancreatic cancer
43. Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreatic cancer: A regimen with unexpected early toxicity